Envista (NVST) Projected to Post Quarterly Earnings on Thursday

Envista (NYSE:NVST) is projected to announce its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $639.4920 million for the quarter. Envista has set its FY 2025 guidance at 1.050-1.15 EPS.Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 5:00 PM ET.

Envista (NYSE:NVST) last issued its earnings results on Thursday, July 31st. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.02. Envista had a return on equity of 4.84% and a net margin of 2.11%.The company had revenue of $682.10 million during the quarter, compared to analysts’ expectations of $638.21 million. During the same period in the prior year, the business posted $0.11 EPS. Envista’s quarterly revenue was up 7.7% compared to the same quarter last year. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Envista Price Performance

NVST opened at $20.06 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.44 and a quick ratio of 2.08. The stock’s 50 day simple moving average is $20.57 and its 200 day simple moving average is $19.29. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of 62.69, a PEG ratio of 1.11 and a beta of 1.01. Envista has a 1 year low of $14.22 and a 1 year high of $23.00.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NVST. Mizuho raised their target price on shares of Envista from $15.00 to $18.00 and gave the stock an “underperform” rating in a report on Friday, August 1st. Morgan Stanley boosted their price objective on shares of Envista from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Evercore ISI set a $25.00 price objective on shares of Envista in a research note on Wednesday, October 8th. Wells Fargo & Company boosted their price target on Envista from $17.00 to $19.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Finally, Piper Sandler upped their price target on Envista from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $21.08.

Hedge Funds Weigh In On Envista

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVST. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Envista by 73.1% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after buying an additional 949 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Envista by 378.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after acquiring an additional 1,909 shares during the period. Captrust Financial Advisors lifted its position in Envista by 38.4% during the 2nd quarter. Captrust Financial Advisors now owns 15,465 shares of the company’s stock valued at $302,000 after acquiring an additional 4,290 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in Envista during the second quarter worth about $318,000. Finally, Prudential Financial Inc. grew its holdings in Envista by 22.1% in the second quarter. Prudential Financial Inc. now owns 18,785 shares of the company’s stock worth $367,000 after purchasing an additional 3,395 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.